250 Direct healthcare cost of atopic dermatitis in the Swedish population 1 Lindberg, 2 A de Geer, 3 G Ortsæter, 1 A Rieem Dun, 1 K Geale, 1 JP Thyssen, 4 L Von Krogh, 2 N Perngner, 1 G Capellini, 2 W Romersni, 1 and M Neary 1 Quantity Research, Stockholm, Sweden, 2 Pfizer AB, Sollentuna, Sweden, 3 Public Health & Clinical Medicine, Umeå University, Umeå, Sweden, 4 Dermatology & Venereology, Bispebjerg Hospital, Copenhagen, Denmark, Ribe, Denmark, 5 National Institute of Environmental Medicine, Uppsala, Sweden, 6 Institut Médical Sciences, Ordrup University, Ordrup, Sweden, 7 Pfizer Inc, NY, New York, United States, 8 Pfizer Inc, Groton, Connecticut, United States, 9 Pfizer Ltd, London, United Kingdom and 10 Pfizer Inc, Collegville, Pennsylvania, United States.

Atopic dermatitis (AD) is a chronic inflammatory skin disorder affecting the general population. The aim of this study was to determine the direct healthcare cost of AD in Sweden. The study was a retrospective cost analysis of AD patients sampled from the Swedish National Patient Registry (SNPR). Total costs were estimated by dividing the number of AD diagnoses by the direct healthcare cost per diagnosis. AD was defined as ICD-10 code L40.x. Total costs were €183,000,000, corresponding to 0.56% of total healthcare costs in Sweden. The cost of AD was highest in children under 16 years of age (€145,000,000), followed by adults (€38,000,000). The direct healthcare cost per diagnosis was highest in municipalities with a low AD prevalence. The results indicate that AD is a significant burden on the healthcare system, highlighting the need for preventive measures to reduce healthcare costs.